Serhat Aras | Health Professions | Best Researcher Award

Assoc. Prof. Dr. Serhat Aras | Health Professions | Best Researcher Award

Assoc. Prof. Dr. Serhat Aras, University of Health Sciences Turkey, Turkey

Assoc. Prof. Dr. Serhat Aras is a nuclear physicist with a Ph.D. from Manisa Celal Bayar University, where he focused on Monte Carlo methods in dose calculations for prostate brachytherapy. He currently serves at the University of Health Sciences, Istanbul, specializing in medical imaging and radiological sciences. Dr. Aras has led research on the radiobiological effects of advanced radiation techniques in cancer treatments, including studies on breast and lung cancer. His teaching includes courses on radiologic imaging, radiation safety, and nuclear medicine. In 2023, he received an International Research Award in India. πŸ§ͺπŸ“‘πŸ‘¨β€πŸ«

 

Publication Profile

Google Scholar


Academic Background

Dr. Aras completed his PhD in Nuclear Physics at Celal Bayar University, focusing on advanced methodologies for calculating patient doses in prostate brachytherapy using Monte Carlo simulations. His Master’s research also focused on dose distribution in brachytherapy, providing a solid foundation for his contributions to medical physics. His specialized education enhances his capacity to innovate in patient-specific dosimetry, an essential area in clinical radiotherapy.

Professional Experience

Dr. Aras serves in the Medical Imaging Techniques Program at Istanbul Health Sciences University. His roles have included Assistant Professor and Lecturer, where he has imparted his knowledge in courses such as Radiologic Imaging Physics, Radiation Safety, and Nuclear Medicine. His expertise in radiology and medical physics makes him an asset to the field, both in research and education, as he prepares future professionals in these highly technical fields.

Research Projects

Dr. Aras has led numerous research projects in radiobiology and oncology, demonstrating his commitment to advancing medical science. His projects include the study of radiobiological impacts on non-small cell lung cancer xenografts and the protective effects of melatonin and probiotics against radiation-induced tissue damage in experimental rat models. His role as a principal investigator in these studies reflects his leadership and research aptitude, focusing on innovative approaches to radiotherapy and radiation protection.

Awards and Recognition

Dr. Aras received the 2023 International Research Award from ISSN, India, which highlights his global research impact. This accolade, along with his publication record, underscores his contributions to nuclear and medical physics on an international level.

Conclusion

Assoc. Prof. Dr. Serhat Aras’s extensive research in medical imaging, radiotherapy, and radiobiological protection, combined with his teaching and leadership roles, makes him a suitable and commendable candidate for the Best Researcher Award. His contributions to nuclear physics applications in medicine reflect both a commitment to scientific advancement and a positive impact on clinical practices.

 

Publication Top Notes  

  • Dosimetric comparison of three-dimensional conformal radiotherapy (3D-CRT) and intensity modulated radiotherapy techniques (IMRT) with radiotherapy dose simulations for left breast cancer πŸ’‰ – Cited by: 41, Year: 2019
  • Dosimetric comparison of superflab and specially prepared bolus materials used in radiotherapy practice πŸ“ – Cited by: 27, Year: 2020
  • The role of melatonin on acute thyroid damage induced by high dose rate X-ray in head and neck radiotherapy πŸŒ™ – Cited by: 12, Year: 2021
  • Radioprotective effect of melatonin against radiotherapy-induced cerebral cortex and cerebellum damage in rat 🐭 – Cited by: 11, Year: 2020
  • Radiobiological comparison of flattening filter (FF) and flattening filter free (FFF) beam in rat laryngeal tissue πŸ”¬ – Cited by: 8, Year: 2020
  • Home care for mastectomy patients πŸ₯ – Cited by: 0, Year: 2008
  • A survey study of radiation protection awareness among radiology technicians in Mogadishu, Somalia 🌍 – Cited by: 7, Year: 2020
  • Thoracic re-irradiation for locally recurrent lung cancer 🫁 – Cited by: 5, Year: 2016
  • The dosimetric comparison and evaluation of helical tomotherapy, volumetric-modulated arc radiotherapy (VMAT), step-and-shoot and sliding window radiotherapy techniques in breast cancer πŸ’» – Cited by: 4, Year: 2022
  • Effect of Flattening Filter and Flattening Filter Free beams on radiotherapy-induced peripheral blood cell damage βš—οΈ – Cited by: 4, Year: 2021

 

 

 

 

 

Min-ran Li | Medicine and Dentistry | Women Researcher Award

Ms. Min-ran Li | Medicine and Dentistry | Women Researcher Award

Ms. Min-ran Li, The First Affiliated Hospital of Jinan University, China

Dr. Minran Li is the Chief Physician at the Division of Infectious Disease at The First Affiliated Hospital of Jinan University. He earned his M.D. in Internal Medicine from Peking University and has extensive expertise in infectious diseases, particularly nonalcoholic steatohepatitis (NASH) and chronic hepatitis B. His research focuses on discovering noninvasive biomarkers and the molecular mechanisms behind liver diseases. Dr. Li has published numerous articles and has been recognized as a Guangdong High-Level Personnel of Young Talents. πŸ₯πŸ“š

Publication Profile

Scopus

 

Education

Ms. Li holds an M.D. in Internal Medicine (Infectious Disease) from Beijing Peking University, a Master’s in Internal Medicine from Hebei Medical University, and a Bachelor’s in Clinical Medicine. This strong educational foundation has empowered her expertise in infectious diseases, particularly liver-related conditions like NASH (nonalcoholic steatohepatitis) and CHB (chronic hepatitis B).

Work Experience

Currently serving as Chief Physician in the Division of Infectious Diseases at the First Affiliated Hospital of Jinan University, Ms. Li has progressively taken on roles of increasing responsibility, including as Associate Chief Physician at The Fifth Hospital of Shijiazhuang. Her work centers on managing liver diseases and exploring innovative biomarkers.

Research Interests

Her research focuses on discovering noninvasive biomarkers for pathological features of NASH in combination with CHB. Her findings on the role of HIGD1A and fibrosis development in liver disease have been pivotal in identifying therapeutic targets, advancing the understanding of liver disease progression.

Awards and Recognitions

Her dedication has been recognized with honors such as the Guangdong High-Level Personnel of Young Talents Program and the Yangcheng Good Doctor Award, underscoring her excellence in medical research and practice.

Conclusion

Ms. Min-ran Li’s strong academic background, leadership in liver disease research, and national and international recognition make her a strong candidate for the Research for Women Researcher Award.

 

Publication Top Notes

  • Pan, Y. et al. (2024). Overexpression of LAG-3: a potential indicator of low immune function in tuberculosis. Frontiers in Cellular and Infection Microbiology, 14, 1410015. 🦠 (0 citations)
  • Li, M.-R. et al. (2024). The function role of HIGD1A in nonalcoholic steatohepatitis from chronic hepatitis B. Scandinavian Journal of Gastroenterology, 59(4), 445–455. πŸ₯— (0 citations)
  • Li, J.-Z. et al. (2023). Mechanism and Progress of Natural Products in the Treatment of NAFLD-Related Fibrosis. Molecules, 28(23), 7936. 🌿 (0 citations)
  • Li, M.-R. et al. (2023). Clinical Features of Non-Alcoholic Fatty Liver Disease in the Non-Lean Population. Obesity Facts, 16(5), 427–434. πŸ” (1 citation)
  • Pan, Y. et al. (2023). Immune checkpoint inhibitors in cancer patients with COVID-19. Open Life Sciences, 18(1), 20220641. πŸ’‰ (1 citation)
  • Li, J.-Z. et al. (2022). Characteristics and treatment strategies for hepatocellular carcinoma caused by nonalcoholic fatty liver disease. Zhonghua gan zang bing za zhi, 30(12), 1392–1396. πŸ₯ (0 citations)
  • Yang, L. et al. (2022). Progress in research of lipogenesis inhibitors for treatment of nonalcoholic fatty liver disease. World Chinese Journal of Digestology, 30(16), 735–742. 🧬 (1 citation)
  • Li, J.-Z. et al. (2021). The identify role and molecular mechanism of the MALAT1/hsa-mir-20b-5p/TXNIP axis in liver inflammation caused by CHB in patients with chronic HBV infection complicated with NAFLD. Virus Research, 298, 198405. πŸ”¬ (20 citations)
  • Zheng, X.-L. et al. (2021). Effect of optimizing oxygen therapy on multiple organ function and prognosis of patients with COVID-19. Chinese Journal of Pathophysiology, 37(5), 909–914. 🫁 (0 citations)
  • Li, M.-R. et al. (2020). Clinical features of hepatitis B patients at immune-tolerance phase with basal core promoter and/or precore mutations. Journal of Viral Hepatitis, 27(10), 1044–1051. 🦠 (4 citations)